Pharvaris NV announced clinical data for deucrictibant, an oral bradykinin B2 receptor antagonist being developed for hereditary angioedema $(HAE)$, highlighting results from the Phase 3 placebo-controlled RAPIDe-3 study and final long-term findings from the Phase 2 CHAPTER-1 open-label extension. The company said these results were presented at the American Academy of Allergy, Asthma & Immunology (AAAAI) 2026 Annual Meeting, including RAPIDe-3 outcomes showing a median 1.28 hours to onset of symptom relief and 11.95 hours to complete symptom resolution versus placebo, and CHAPTER-1 data reporting a reduction in mean attack rate from 2.18 attacks/month at baseline to 0.12 attacks/month during the extension. Pharvaris also presented Phase 1 pharmacokinetic data supporting once-daily dosing of an extended-release deucrictibant tablet for prophylaxis.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pharvaris NV published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603020650PRIMZONEFULLFEED9663759) on March 02, 2026, and is solely responsible for the information contained therein.